Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28185141,Onset of appearance,"Onset of appearance (~3 min), time to 50% of maximum concentration (t Early 50% Cmax; ~20 min) and time to maximum concentration (t max; ~55 min) were all similar between injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),min,3,8291,DB01306,Insulin Aspart
,28185141,time to 50% of maximum concentration (t Early 50% Cmax,"Onset of appearance (~3 min), time to 50% of maximum concentration (t Early 50% Cmax; ~20 min) and time to maximum concentration (t max; ~55 min) were all similar between injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),min,20,8292,DB01306,Insulin Aspart
,28185141,time to maximum concentration (t max,"Onset of appearance (~3 min), time to 50% of maximum concentration (t Early 50% Cmax; ~20 min) and time to maximum concentration (t max; ~55 min) were all similar between injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),min,55,8293,DB01306,Insulin Aspart
,28185141,absolute bioavailability,"Total exposure (AUCIAsp,0-t) was similar for the abdomen, upper arm and thigh, and absolute bioavailability was ~80% after subcutaneous administration of faster aspart in all three injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),%,80,8294,DB01306,Insulin Aspart
,11009049,time to maximum serum insulin concentration (tmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),min,60,10995,DB01306,Insulin Aspart
,11009049,time to maximum serum insulin concentration (tmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),min,110,10996,DB01306,Insulin Aspart
,11009049,maximum insulin concentration (Cmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),[mu] / [l],23.4,10997,DB01306,Insulin Aspart
,11009049,maximum insulin concentration (Cmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),[mu] / [l],15.5,10998,DB01306,Insulin Aspart
,30565407,AUCins,"BCLIS also demonstrated significantly higher early exposure (AUCins, 0-60 minutes) and lower late exposure (AUCins,120-600 minutes) than both other insulins.",BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30565407/),min,0-60,25782,DB01306,Insulin Aspart
,30565407,AUCins,"BCLIS also demonstrated significantly higher early exposure (AUCins, 0-60 minutes) and lower late exposure (AUCins,120-600 minutes) than both other insulins.",BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30565407/),min,120-600,25783,DB01306,Insulin Aspart
,10923219,maximum serum insulin (Cmax ins),"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),[pM] / [l],881,50241,DB01306,Insulin Aspart
,10923219,maximum serum insulin (Cmax ins),"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),[pM] / [l],422,50242,DB01306,Insulin Aspart
,10923219,tmax ins,"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),min,40.0,50243,DB01306,Insulin Aspart
,10923219,tmax ins,"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),min,75.0,50244,DB01306,Insulin Aspart
,26259978,time,"The jet injector advanced this time to 147.9 ± 14.4 min [difference 44.6 (95% confidence interval 4.3, 84.8); P = 0.03], except in 3 patients who failed to reach this endpoint.",Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),min,147.9,51462,DB01306,Insulin Aspart
exceeded,26259978,time advantage,The time advantage exceeded 1.5 h in patients with a BMI above the median.,Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),h,1.5,51463,DB01306,Insulin Aspart
,26259978,time to peak insulin levels,"Jet injection also reduced the hyperglycaemic burden during the first 2 h (2042 ± 37.2 vs 2168 ± 26.1 mmol/min; P = 0.01) and the time to peak insulin levels (40.5 ± 3.2 vs 76.8 ± 7.7 min; P < 0.001), but did not increase the risk for hypoglycaemia.",Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),min,40.5,51464,DB01306,Insulin Aspart
,26259978,time to peak insulin levels,"Jet injection also reduced the hyperglycaemic burden during the first 2 h (2042 ± 37.2 vs 2168 ± 26.1 mmol/min; P = 0.01) and the time to peak insulin levels (40.5 ± 3.2 vs 76.8 ± 7.7 min; P < 0.001), but did not increase the risk for hypoglycaemia.",Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),min,76.8,51465,DB01306,Insulin Aspart
,23278690,half-life (t(1/2) ),"The half-life (t(1/2) ) was 24.3 (range 17.3-41.3), 28.8 (range 19.6-54.3) and 23.6 (range 17.4-36.8) min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,24.3,51940,DB01306,Insulin Aspart
,23278690,half-life (t(1/2) ),"The half-life (t(1/2) ) was 24.3 (range 17.3-41.3), 28.8 (range 19.6-54.3) and 23.6 (range 17.4-36.8) min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,28.8,51941,DB01306,Insulin Aspart
,23278690,half-life (t(1/2) ),"The half-life (t(1/2) ) was 24.3 (range 17.3-41.3), 28.8 (range 19.6-54.3) and 23.6 (range 17.4-36.8) min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,23.6,51942,DB01306,Insulin Aspart
,23278690,area under the curve per dose (AUC/D),"The area under the curve per dose (AUC/D) was determined to be 51.2 ± 19.5, 52.3 ± 12.5 and 51.6 ± 6.7 pm × min/kg for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),[min·pm] / [kg],51.2,51943,DB01306,Insulin Aspart
,23278690,area under the curve per dose (AUC/D),"The area under the curve per dose (AUC/D) was determined to be 51.2 ± 19.5, 52.3 ± 12.5 and 51.6 ± 6.7 pm × min/kg for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),[min·pm] / [kg],52.3,51944,DB01306,Insulin Aspart
,23278690,area under the curve per dose (AUC/D),"The area under the curve per dose (AUC/D) was determined to be 51.2 ± 19.5, 52.3 ± 12.5 and 51.6 ± 6.7 pm × min/kg for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),[min·pm] / [kg],51.6,51945,DB01306,Insulin Aspart
,23278690,steady state plasma concentration (C(ss) ),"The steady state plasma concentration (C(ss) ) was 57.5 ± 27.1, 54.3 ± 10.3 and 55.1 ± 8.0 pm (mean ± SD) for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),pm,57.5,51946,DB01306,Insulin Aspart
,23278690,steady state plasma concentration (C(ss) ),"The steady state plasma concentration (C(ss) ) was 57.5 ± 27.1, 54.3 ± 10.3 and 55.1 ± 8.0 pm (mean ± SD) for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),pm,54.3,51947,DB01306,Insulin Aspart
,23278690,steady state plasma concentration (C(ss) ),"The steady state plasma concentration (C(ss) ) was 57.5 ± 27.1, 54.3 ± 10.3 and 55.1 ± 8.0 pm (mean ± SD) for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),pm,55.1,51948,DB01306,Insulin Aspart
,23278690,Time to steady state (T(ss) ),"Time to steady state (T(ss) ) was 110 ± 36, 98 ± 48 and 90 ± 27 min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,110,51949,DB01306,Insulin Aspart
,23278690,Time to steady state (T(ss) ),"Time to steady state (T(ss) ) was 110 ± 36, 98 ± 48 and 90 ± 27 min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,98,51950,DB01306,Insulin Aspart
,23278690,Time to steady state (T(ss) ),"Time to steady state (T(ss) ) was 110 ± 36, 98 ± 48 and 90 ± 27 min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,90,51951,DB01306,Insulin Aspart
,19764836,ATBF,ATBF increased from day 0 to day 2 after catheter insertion (2.6 +/- 0.6 to 4.5 +/- 0.8 mL/100 g/min; P = 0.030).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),[ml] / [100·g·min],2.6,55143,DB01306,Insulin Aspart
,19764836,ATBF,ATBF increased from day 0 to day 2 after catheter insertion (2.6 +/- 0.6 to 4.5 +/- 0.8 mL/100 g/min; P = 0.030).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),[ml] / [100·g·min],4.5,55144,DB01306,Insulin Aspart
,19764836,Time to peak plasma insulin aspart concentration,Time to peak plasma insulin aspart concentration after bolus administration decreased with catheter wear-time from 55 +/- 3 min on day 0 to 45 +/- 4 min on day 4 (P = 0.019).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),min,55,55145,DB01306,Insulin Aspart
,19764836,Time to peak plasma insulin aspart concentration,Time to peak plasma insulin aspart concentration after bolus administration decreased with catheter wear-time from 55 +/- 3 min on day 0 to 45 +/- 4 min on day 4 (P = 0.019).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),min,45,55146,DB01306,Insulin Aspart
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.2,71255,DB01306,Insulin Aspart
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.5,71256,DB01306,Insulin Aspart
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.4,71257,DB01306,Insulin Aspart
,12518253,t min,For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,59.3,71258,DB01306,Insulin Aspart
,12518253,t min,For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,63.5,71259,DB01306,Insulin Aspart
,12518253,C-peptide,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],225,71260,DB01306,Insulin Aspart
,12518253,C-peptide,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],309,71261,DB01306,Insulin Aspart
,12518253,C-peptide concentrations,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],117,71262,DB01306,Insulin Aspart
,12518253,C-peptide concentrations,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],105,71263,DB01306,Insulin Aspart
,12518253,maximal concentration,The maximal concentration of insulin was detected in both groups after 40 min (lispro 20.8 +/- 1.1 mU/l versus aspart 24.6 +/- 1.3 mU/l; p = 0.032).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mu] / [l],20.8,71264,DB01306,Insulin Aspart
,12518253,maximal concentration,The maximal concentration of insulin was detected in both groups after 40 min (lispro 20.8 +/- 1.1 mU/l versus aspart 24.6 +/- 1.3 mU/l; p = 0.032).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mu] / [l],24.6,71265,DB01306,Insulin Aspart
,12518253,t max,For insulin t max was 33.0 +/- 2.6 min in the aspart versus 33.3 +/- 2.6 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,33.0,71266,DB01306,Insulin Aspart
,12518253,t max,For insulin t max was 33.0 +/- 2.6 min in the aspart versus 33.3 +/- 2.6 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,33.3,71267,DB01306,Insulin Aspart
,28303726,T-INSmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,7.3,74711,DB01306,Insulin Aspart
,28303726,T-INSmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,22.3,74712,DB01306,Insulin Aspart
,28303726,T-GIRmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,24.0,74713,DB01306,Insulin Aspart
,28303726,T-GIRmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,27.3,74714,DB01306,Insulin Aspart
,19539098,post,The mean (SD) postprandial glucose excursion AUC at 120 minutes after the meal was significantly reduced in the group that used the device compared with the group that did not (104 [65] vs 155 [56] mg/dL/h; P < 0.005).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mg] / [dl·h],104,77439,DB01306,Insulin Aspart
,19539098,T(max),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,45,77440,DB01306,Insulin Aspart
,19539098,T(max),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,78,77441,DB01306,Insulin Aspart
,19539098,time to half-maximum concentration (T(50%max)),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,20,77442,DB01306,Insulin Aspart
,19539098,time to half-maximum concentration (T(50%max)),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,28,77443,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],21,77444,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],33,77445,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],60,77446,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],55,77447,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],80,77448,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],90,77449,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],93,77450,DB01306,Insulin Aspart
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],118,77451,DB01306,Insulin Aspart
,19539098,Cmax,Cmax also increased significantly (118 [35] vs 86 [16] mU/L [38%]; P < 0.05).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [l],118,77452,DB01306,Insulin Aspart
,19539098,Cmax,Cmax also increased significantly (118 [35] vs 86 [16] mU/L [38%]; P < 0.05).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [l],86,77453,DB01306,Insulin Aspart
,12077738,Maximum serum glucose concentration (C(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),[mM] / [l],14.0,84326,DB01306,Insulin Aspart
,12077738,Maximum serum glucose concentration (C(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),[mM] / [l],16.5,84327,DB01306,Insulin Aspart
,12077738,time to maximal serum glucose concentration (t(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),min,20,84328,DB01306,Insulin Aspart
,24286115,area under the glucose concentration-time curve for 0-240 min,"In this small pilot study, the devices were similar in glucose excursion (median [quartile 1, quartile 3], InsuJet vs. FlexPen, 9.4 [4.8, 12.8] vs. 8.1 [5.4, 10.6] mmol/L; P=0.43), in the area under the glucose concentration-time curve for 0-240 min corrected for baseline glucose level (InsuJet vs. FlexPen, 1,230 [623, 2,012] vs. 1,175 [91, 1,774] mmol · min/L; P=0.4), and in insulin absorption over the 240-min period.",A pilot study to examine the tolerability and device preference in type 1 diabetes of insulin aspart administered by InsuJet compared with subcutaneous injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24286115/),[mM·min] / [l],"1,230",91465,DB01306,Insulin Aspart
,24286115,area under the glucose concentration-time curve for 0-240 min,"In this small pilot study, the devices were similar in glucose excursion (median [quartile 1, quartile 3], InsuJet vs. FlexPen, 9.4 [4.8, 12.8] vs. 8.1 [5.4, 10.6] mmol/L; P=0.43), in the area under the glucose concentration-time curve for 0-240 min corrected for baseline glucose level (InsuJet vs. FlexPen, 1,230 [623, 2,012] vs. 1,175 [91, 1,774] mmol · min/L; P=0.4), and in insulin absorption over the 240-min period.",A pilot study to examine the tolerability and device preference in type 1 diabetes of insulin aspart administered by InsuJet compared with subcutaneous injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24286115/),[mM·min] / [l],"1,175",91466,DB01306,Insulin Aspart
,29101821,duration of action,"When compared to the PD data that have been reported for regular insulin in healthy cats, insulin aspart had a more rapid onset (IM: 10 min [10-21.25 min], SC: 12.5 min [10-18.75 min]) and shorter duration of action (IM: 182.5 ± 34.33 min, SC: 159.38 ± 41.87 min).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),min,182.5,97437,DB01306,Insulin Aspart
,29101821,duration of action,"When compared to the PD data that have been reported for regular insulin in healthy cats, insulin aspart had a more rapid onset (IM: 10 min [10-21.25 min], SC: 12.5 min [10-18.75 min]) and shorter duration of action (IM: 182.5 ± 34.33 min, SC: 159.38 ± 41.87 min).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),min,159.38,97438,DB01306,Insulin Aspart
,29101821,maximum plasma insulin aspart concentration,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"1,265.17",97439,DB01306,Insulin Aspart
,29101821,maximum plasma insulin aspart concentration,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"3,278.19",97440,DB01306,Insulin Aspart
,29101821,area under the insulin aspart vs time curve,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"82,662",97441,DB01306,Insulin Aspart
,29101821,area under the insulin aspart vs time curve,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"135,060",97442,DB01306,Insulin Aspart
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,30,102449,DB01306,Insulin Aspart
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,61.3,102450,DB01306,Insulin Aspart
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,39.2,102451,DB01306,Insulin Aspart
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,99.2,102452,DB01306,Insulin Aspart
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],23.0,102453,DB01306,Insulin Aspart
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],9.9,102454,DB01306,Insulin Aspart
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],30.9,102455,DB01306,Insulin Aspart
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],13.3,102456,DB01306,Insulin Aspart
,27500713,Tmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),min,35,108741,DB01306,Insulin Aspart
,27500713,Tmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),min,87.5,108742,DB01306,Insulin Aspart
,27500713,Cmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [ml],80,108743,DB01306,Insulin Aspart
,27500713,Cmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [ml],55,108744,DB01306,Insulin Aspart
,27500713,area under the curve (AUC; 360 min),"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],9914,108745,DB01306,Insulin Aspart
,27500713,area under the curve (AUC; 360 min),"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],"10,936",108746,DB01306,Insulin Aspart
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],3821,108747,DB01306,Insulin Aspart
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],2534,108748,DB01306,Insulin Aspart
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],2054,108749,DB01306,Insulin Aspart
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],2929,108750,DB01306,Insulin Aspart
,27500713,relative bioavailability,The relative bioavailability of the ID versus the SC insulin (AUCID/AUCSC) was similar (median 0.91 [95% confidence interval 0.73-1.27]).,Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),,0.91,108751,DB01306,Insulin Aspart
,20429049,area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min,"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),[mg] / [kg],30.3,112731,DB01306,Insulin Aspart
,20429049,area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min,"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),[mg] / [kg],16.2,112732,DB01306,Insulin Aspart
,20429049,time to 10% of GIR (max) (GIR (max)-t (10%)),"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),min,9,112733,DB01306,Insulin Aspart
,20429049,time to 10% of GIR (max) (GIR (max)-t (10%)),"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),min,17,112734,DB01306,Insulin Aspart
<,22642657,time to maximum concentration (T(max)),"However, the time to maximum concentration (T(max)), which varied widely from < 60 to ≥ 120 min, was not associated with either dosage (r(2) = 0.02; P = 0.51) or body mass index (r(2) = 0.02; P = 0.57).",Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642657/),min,60,117900,DB01306,Insulin Aspart
,22642657,time to maximum concentration (T(max)),"However, the time to maximum concentration (T(max)), which varied widely from < 60 to ≥ 120 min, was not associated with either dosage (r(2) = 0.02; P = 0.51) or body mass index (r(2) = 0.02; P = 0.57).",Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642657/),min,120,117901,DB01306,Insulin Aspart
≥,22642657,T(max),"Injection of insulin aspart exacerbated delayed hyperinsulinaemia after meal loading, mainly in patients with T(max) ≥ 120 min.",Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642657/),min,120,117902,DB01306,Insulin Aspart
,14571692,time course of absorption,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),,1.5,129515,DB01306,Insulin Aspart
,14571692,time course of absorption,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),,2.1,129516,DB01306,Insulin Aspart
,14571692,elimination rate constant,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.010,129517,DB01306,Insulin Aspart
,14571692,elimination rate constant,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.016,129518,DB01306,Insulin Aspart
,14571692,rate of insulin action,"The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.012,129519,DB01306,Insulin Aspart
,14571692,rate of insulin action,"The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.017,129520,DB01306,Insulin Aspart
,24610683,Maximal post-insulin bolus concentration,Maximal post-insulin bolus concentration was 57 mU/L on day 1 InsuPatch versus 47.6 mU/L on day 1 control (p < 0.01).,"Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],57,130150,DB01306,Insulin Aspart
,24610683,Maximal post-insulin bolus concentration,Maximal post-insulin bolus concentration was 57 mU/L on day 1 InsuPatch versus 47.6 mU/L on day 1 control (p < 0.01).,"Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],47.6,130151,DB01306,Insulin Aspart
,24610683,Maximal insulin concentration,"Maximal insulin concentration was 70.4 mU/L versus 57 mU/L, respectively (p = 0.05).","Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],70.4,130152,DB01306,Insulin Aspart
,24610683,Maximal insulin concentration,"Maximal insulin concentration was 70.4 mU/L versus 57 mU/L, respectively (p = 0.05).","Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],57,130153,DB01306,Insulin Aspart
,10379635,tmax(ins),"The absorption of insulin aspart was, on average, more than twice as fast and reached levels more than twice as high compared with human insulin [tmax(ins) of 52 (23) vs 145 (93) min, P < 0.0001; and Cmax(ins) of 41 (11) vs 18 (4) mU x l(-1), P < 0.0001; mean with (SD)].","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),min,52,130272,DB01306,Insulin Aspart
,10379635,tmax(ins),"The absorption of insulin aspart was, on average, more than twice as fast and reached levels more than twice as high compared with human insulin [tmax(ins) of 52 (23) vs 145 (93) min, P < 0.0001; and Cmax(ins) of 41 (11) vs 18 (4) mU x l(-1), P < 0.0001; mean with (SD)].","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),min,145,130273,DB01306,Insulin Aspart
,10379635,Cmax(ins),"The absorption of insulin aspart was, on average, more than twice as fast and reached levels more than twice as high compared with human insulin [tmax(ins) of 52 (23) vs 145 (93) min, P < 0.0001; and Cmax(ins) of 41 (11) vs 18 (4) mU x l(-1), P < 0.0001; mean with (SD)].","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),[mu] / [l],41,130274,DB01306,Insulin Aspart
,10379635,Cmax(ins),"The absorption of insulin aspart was, on average, more than twice as fast and reached levels more than twice as high compared with human insulin [tmax(ins) of 52 (23) vs 145 (93) min, P < 0.0001; and Cmax(ins) of 41 (11) vs 18 (4) mU x l(-1), P < 0.0001; mean with (SD)].","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),[mu] / [l],18,130275,DB01306,Insulin Aspart
,10379635,MRT(ins),"However, total bioavailability did not differ between the insulins, and thus the mean residence time was significantly shorter for insulin aspart [MRT(ins) of 149 (26) vs 217 (30) min, P < 0.0001].","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),min,149,130276,DB01306,Insulin Aspart
,10379635,MRT(ins),"However, total bioavailability did not differ between the insulins, and thus the mean residence time was significantly shorter for insulin aspart [MRT(ins) of 149 (26) vs 217 (30) min, P < 0.0001].","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),min,217,130277,DB01306,Insulin Aspart
,10379635,tmin,"Plasma glucose (PG) fell more than twice as rapidly [tmin(PG) of 94 (45) vs 226 (120) min, P < 0.0001], to a greater extent [Cmin(PG) 2.1 (0.6) vs 1.4 (0.4) mmol x l(-1), P < 0.0001], and for a shorter duration with insulin aspart than with human insulin.","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),min,94,130278,DB01306,Insulin Aspart
,10379635,tmin,"Plasma glucose (PG) fell more than twice as rapidly [tmin(PG) of 94 (45) vs 226 (120) min, P < 0.0001], to a greater extent [Cmin(PG) 2.1 (0.6) vs 1.4 (0.4) mmol x l(-1), P < 0.0001], and for a shorter duration with insulin aspart than with human insulin.","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),min,226,130279,DB01306,Insulin Aspart
,10379635,Cmin,"Plasma glucose (PG) fell more than twice as rapidly [tmin(PG) of 94 (45) vs 226 (120) min, P < 0.0001], to a greater extent [Cmin(PG) 2.1 (0.6) vs 1.4 (0.4) mmol x l(-1), P < 0.0001], and for a shorter duration with insulin aspart than with human insulin.","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),[mM] / [l],2.1,130280,DB01306,Insulin Aspart
,10379635,Cmin,"Plasma glucose (PG) fell more than twice as rapidly [tmin(PG) of 94 (45) vs 226 (120) min, P < 0.0001], to a greater extent [Cmin(PG) 2.1 (0.6) vs 1.4 (0.4) mmol x l(-1), P < 0.0001], and for a shorter duration with insulin aspart than with human insulin.","Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379635/),[mM] / [l],1.4,130281,DB01306,Insulin Aspart
,33159695,"AUCGIR,0-10h","The AUCGIR,0-10h in groups A, B, and C was 1983 ± 650,1682 ± 454, and 1479 ± 440 mg/kg (P = 0.047), respectively, under comparable IAsp exposure.",Oscillations of C-peptide in the euglycemic clamp and their effect on the pharmacodynamic assessment of insulin preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159695/),[mg] / [kg],1983,133761,DB01306,Insulin Aspart
,33159695,"AUCGIR,0-10h","The AUCGIR,0-10h in groups A, B, and C was 1983 ± 650,1682 ± 454, and 1479 ± 440 mg/kg (P = 0.047), respectively, under comparable IAsp exposure.",Oscillations of C-peptide in the euglycemic clamp and their effect on the pharmacodynamic assessment of insulin preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159695/),[mg] / [kg],1682,133762,DB01306,Insulin Aspart
,33159695,"AUCGIR,0-10h","The AUCGIR,0-10h in groups A, B, and C was 1983 ± 650,1682 ± 454, and 1479 ± 440 mg/kg (P = 0.047), respectively, under comparable IAsp exposure.",Oscillations of C-peptide in the euglycemic clamp and their effect on the pharmacodynamic assessment of insulin preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159695/),[mg] / [kg],1479,133763,DB01306,Insulin Aspart
,31069935,onset of appearance,"Least squares mean (± SE) onset of appearance was 3.3 ± 0.3 minutes for faster aspart, which was 1.2 minutes earlier than for IAsp (95% confidence interval [CI] -1.8;-0.5; P = .001).",Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31069935/),min,3.3,147884,DB01306,Insulin Aspart
,25537835,total daily dose,"Eleven children (six male; age range 3.75-6.96 years, HbA1c 7.6% ± 1.3% [60 ± 14 mmol/mol], BMI standard deviation score 1.0 ± 0.8, duration of diabetes 2.2 ± 1.0 years, total daily dose 12.9 [10.6-16.5] U, fasting C-peptide concentration 5 [5-17.1] pmol/l; mean ± SD or median [interquartile range]) participated in the study.",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),u,12.9,160532,DB01306,Insulin Aspart
,25537835,t max,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,59.2,160533,DB01306,Insulin Aspart
,25537835,t max,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,61.6,160534,DB01306,Insulin Aspart
,25537835,I,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[1] / [kg·min],1.98 × 10(-2),160535,DB01306,Insulin Aspart
,25537835,I,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[1] / [kg·min],1.89 × 10(-2),160536,DB01306,Insulin Aspart
,25537835,ins c,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[pM] / [l],34,160537,DB01306,Insulin Aspart
,25537835,ins c,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[pM] / [l],23,160538,DB01306,Insulin Aspart
,25537835,t max,"However, t max showed less intersubject variability following administration of diluted aspart (SD 14.4 vs 8.7 min, p = 0.047).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,14.4,160539,DB01306,Insulin Aspart
,25537835,t max,"However, t max showed less intersubject variability following administration of diluted aspart (SD 14.4 vs 8.7 min, p = 0.047).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,8.7,160540,DB01306,Insulin Aspart
,9802742,time to maximal metabolic activity,"Subcutaneous injection of the insulin preparations resulted in intraindividual CVs of the summary measures between 10 and 30% (soluble insulin vs. insulin aspart: maximal metabolic activity 15+/-7 vs. 16+/-10%, time to maximal metabolic activity 14+/-10 vs. 11+/-6%; NS between the preparations [means +/- SD]).",Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802742/),%,14,198171,DB01306,Insulin Aspart
,9802742,time to maximal metabolic activity,"Subcutaneous injection of the insulin preparations resulted in intraindividual CVs of the summary measures between 10 and 30% (soluble insulin vs. insulin aspart: maximal metabolic activity 15+/-7 vs. 16+/-10%, time to maximal metabolic activity 14+/-10 vs. 11+/-6%; NS between the preparations [means +/- SD]).",Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9802742/),%,11,198172,DB01306,Insulin Aspart
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,35,202151,DB01306,Insulin Aspart
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,18,202152,DB01306,Insulin Aspart
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,125,202153,DB01306,Insulin Aspart
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,90,202154,DB01306,Insulin Aspart
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,125,202155,DB01306,Insulin Aspart
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,90,202156,DB01306,Insulin Aspart
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,58,202157,DB01306,Insulin Aspart
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,40,202158,DB01306,Insulin Aspart
,31999478,Tmax,"Results: Tmax was 68.7 ± 21.6 min for faster aspart and 89.7 ± 31.8 min for aspart (mean paired difference faster aspart minus aspart -15.5 min, 95% CI [-31.6 to 0.6 min], P = 0.06).",Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31999478/),min,68.7,205987,DB01306,Insulin Aspart
,31999478,Tmax,"Results: Tmax was 68.7 ± 21.6 min for faster aspart and 89.7 ± 31.8 min for aspart (mean paired difference faster aspart minus aspart -15.5 min, 95% CI [-31.6 to 0.6 min], P = 0.06).",Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31999478/),min,89.7,205988,DB01306,Insulin Aspart
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[pM] / [l],"66,232",213887,DB01306,Insulin Aspart
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[pM] / [l],"48,852",213888,DB01306,Insulin Aspart
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[mg] / [kg·min],"8,928",213889,DB01306,Insulin Aspart
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[mg] / [kg·min],"6,805",213890,DB01306,Insulin Aspart
,10480516,Cmax,"The pharmacodynamic data from the euglycemic clamp study showed that, regardless of injection site, the maximal glucose infusion rate (GIR Cmax) was greater and occurred at an earlier time (GIR Tmax) after administration of insulin aspart than regular insulin (GIR Cmax: abdomen 813 vs. 708, deltoid 861 vs. 736, and thigh 857 vs.",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),,813,226218,DB01306,Insulin Aspart
,10480516,Cmax,"The pharmacodynamic data from the euglycemic clamp study showed that, regardless of injection site, the maximal glucose infusion rate (GIR Cmax) was greater and occurred at an earlier time (GIR Tmax) after administration of insulin aspart than regular insulin (GIR Cmax: abdomen 813 vs. 708, deltoid 861 vs. 736, and thigh 857 vs.",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),,708,226219,DB01306,Insulin Aspart
,10480516,Cmax,"The pharmacodynamic data from the euglycemic clamp study showed that, regardless of injection site, the maximal glucose infusion rate (GIR Cmax) was greater and occurred at an earlier time (GIR Tmax) after administration of insulin aspart than regular insulin (GIR Cmax: abdomen 813 vs. 708, deltoid 861 vs. 736, and thigh 857 vs.",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),,861,226220,DB01306,Insulin Aspart
,10480516,Cmax,"The pharmacodynamic data from the euglycemic clamp study showed that, regardless of injection site, the maximal glucose infusion rate (GIR Cmax) was greater and occurred at an earlier time (GIR Tmax) after administration of insulin aspart than regular insulin (GIR Cmax: abdomen 813 vs. 708, deltoid 861 vs. 736, and thigh 857 vs.",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),,736,226221,DB01306,Insulin Aspart
,10480516,Cmax,"The pharmacodynamic data from the euglycemic clamp study showed that, regardless of injection site, the maximal glucose infusion rate (GIR Cmax) was greater and occurred at an earlier time (GIR Tmax) after administration of insulin aspart than regular insulin (GIR Cmax: abdomen 813 vs. 708, deltoid 861 vs. 736, and thigh 857 vs.",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),,857,226222,DB01306,Insulin Aspart
,10480516,Tmax,"720 g/min, P < 0.05 for all; GIR Tmax: abdomen 94 vs. 173, deltoid 111 vs. 192, and thigh 145 vs. 193 g/min, P < 0.05 for all).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[g] / [min],94,226223,DB01306,Insulin Aspart
,10480516,Tmax,"720 g/min, P < 0.05 for all; GIR Tmax: abdomen 94 vs. 173, deltoid 111 vs. 192, and thigh 145 vs. 193 g/min, P < 0.05 for all).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[g] / [min],173,226224,DB01306,Insulin Aspart
,10480516,Tmax,"720 g/min, P < 0.05 for all; GIR Tmax: abdomen 94 vs. 173, deltoid 111 vs. 192, and thigh 145 vs. 193 g/min, P < 0.05 for all).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[g] / [min],111,226225,DB01306,Insulin Aspart
,10480516,Tmax,"720 g/min, P < 0.05 for all; GIR Tmax: abdomen 94 vs. 173, deltoid 111 vs. 192, and thigh 145 vs. 193 g/min, P < 0.05 for all).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[g] / [min],192,226226,DB01306,Insulin Aspart
,10480516,Tmax,"720 g/min, P < 0.05 for all; GIR Tmax: abdomen 94 vs. 173, deltoid 111 vs. 192, and thigh 145 vs. 193 g/min, P < 0.05 for all).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[g] / [min],145,226227,DB01306,Insulin Aspart
,10480516,Tmax,"720 g/min, P < 0.05 for all; GIR Tmax: abdomen 94 vs. 173, deltoid 111 vs. 192, and thigh 145 vs. 193 g/min, P < 0.05 for all).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[g] / [min],193,226228,DB01306,Insulin Aspart
,10480516,Cmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[pM] / [l],501,226229,DB01306,Insulin Aspart
,10480516,Cmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[pM] / [l],260,226230,DB01306,Insulin Aspart
,10480516,Cmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[pM] / [l],506,226231,DB01306,Insulin Aspart
,10480516,Cmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[pM] / [l],252,226232,DB01306,Insulin Aspart
,10480516,Cmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[pM] / [l],422,226233,DB01306,Insulin Aspart
,10480516,Cmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),[pM] / [l],220,226234,DB01306,Insulin Aspart
,10480516,Tmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),min,52,226235,DB01306,Insulin Aspart
,10480516,Tmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),min,109,226236,DB01306,Insulin Aspart
,10480516,Tmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),min,54,226237,DB01306,Insulin Aspart
,10480516,Tmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),min,98,226238,DB01306,Insulin Aspart
,10480516,Tmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),min,60,226239,DB01306,Insulin Aspart
,10480516,Tmax,"From all sites, the peak insulin concentration (Cmax) was higher and occurred earlier (Tmax) after administration of insulin aspart than of regular insulin (Cmax: abdomen 501 vs. 260, deltoid 506 vs. 252, thigh 422 vs. 220 pmol/l, P < 0.001 for all sites; Tmax: abdomen 52 vs. 109, deltoid 54 vs. 98, and thigh 60 vs. 107 min, P < 0.01 for all sites).",Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480516/),min,107,226240,DB01306,Insulin Aspart
,24089542,time until peak plasma insulin level,Insulin administration by jet injection resulted in shorter time until peak plasma insulin level (51.3 ± 6.4 vs. 91.9 ± 10.2 min; P = 0.003) and reduced hyperglycemic burden during the first hour (154.3 ± 20.8 vs.,Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089542/),min,51.3,234222,DB01306,Insulin Aspart
,24089542,time until peak plasma insulin level,Insulin administration by jet injection resulted in shorter time until peak plasma insulin level (51.3 ± 6.4 vs. 91.9 ± 10.2 min; P = 0.003) and reduced hyperglycemic burden during the first hour (154.3 ± 20.8 vs.,Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089542/),min,91.9,234223,DB01306,Insulin Aspart
,21219436,absolute bioavailability,"Thus, absolute bioavailability was near 100% for both subcutaneous bolus insulin injection and continuous subcutaneous insulin infusion.","Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219436/),%,100,236598,DB01306,Insulin Aspart
,24351176,time-to-peak plasma concentrations [t(max),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),min,51,250895,DB01306,Insulin Aspart
,24351176,t(max),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),min,19,250896,DB01306,Insulin Aspart
,24351176,metabolic clearance rate,"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[l] / [kg·min],0.019,250897,DB01306,Insulin Aspart
,24351176,metabolic clearance rate,"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[l] / [kg·min],0.012,250898,DB01306,Insulin Aspart
,24351176,I(b),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[mu] / [l],10.2,250899,DB01306,Insulin Aspart
,24351176,I(b),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[pg] / [ml],50,250900,DB01306,Insulin Aspart
,21715522,time to maximal GIR,"The time to maximal GIR was significantly shorter when insulin was injected with the jet injector compared with conventional pen administration (51 ± 3 vs. 105 ± 11 min, P < 0.0001).",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,51,250971,DB01306,Insulin Aspart
,21715522,time to maximal GIR,"The time to maximal GIR was significantly shorter when insulin was injected with the jet injector compared with conventional pen administration (51 ± 3 vs. 105 ± 11 min, P < 0.0001).",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,105,250972,DB01306,Insulin Aspart
,21715522,time to peak insulin concentration,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,31,250973,DB01306,Insulin Aspart
,21715522,time to peak insulin concentration,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,64,250974,DB01306,Insulin Aspart
,21715522,peak insulin concentrations,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),[mu] / [l],108,250975,DB01306,Insulin Aspart
,21715522,peak insulin concentrations,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),[mu] / [l],79,250976,DB01306,Insulin Aspart
,25846340,onset of appearance,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,4.9,251051,DB01306,Insulin Aspart
,25846340,onset of appearance,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,11.2,251052,DB01306,Insulin Aspart
,25846340,time to reach 50% maximum concentration,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,20.7,251053,DB01306,Insulin Aspart
,25846340,time to reach 50% maximum concentration,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,31.6,251054,DB01306,Insulin Aspart
,25846340,time to reach 50% maximum glucose infusion rate,"Faster-acting insulin aspart had a significantly greater glucose-lowering effect within 90 min after dosing [largest difference: area under the curve for the glucose infusion rate (AUC(GIR), 0-30 min) ratio 1.48, 95% CI 1.13; 2.02] and 17% earlier time to reach 50% maximum glucose infusion rate (38.3 vs 46.1 min; ratio 0.83, 95% CI 0.73; 0.94).",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,38.3,251055,DB01306,Insulin Aspart
,25846340,time to reach 50% maximum glucose infusion rate,"Faster-acting insulin aspart had a significantly greater glucose-lowering effect within 90 min after dosing [largest difference: area under the curve for the glucose infusion rate (AUC(GIR), 0-30 min) ratio 1.48, 95% CI 1.13; 2.02] and 17% earlier time to reach 50% maximum glucose infusion rate (38.3 vs 46.1 min; ratio 0.83, 95% CI 0.73; 0.94).",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,46.1,251056,DB01306,Insulin Aspart
,32543150,relative biological effectiveness,The relative biological effectiveness (reflecting gloucose-lowing effect) and bioavailability on behalf of plasma-drug concentration were 98.3±18.8% and 97.3%±8.3% respectively.,"[The Pharmacokinetics, Pharmacodynamics and Bioequivalence of Insulin Aspart Produced by the United Laboratories Evaluated by Euglycemic Clamp Study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32543150/),%,98.3,261131,DB01306,Insulin Aspart
,32543150,bioavailability,The relative biological effectiveness (reflecting gloucose-lowing effect) and bioavailability on behalf of plasma-drug concentration were 98.3±18.8% and 97.3%±8.3% respectively.,"[The Pharmacokinetics, Pharmacodynamics and Bioequivalence of Insulin Aspart Produced by the United Laboratories Evaluated by Euglycemic Clamp Study]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32543150/),%,97.3,261132,DB01306,Insulin Aspart
